ImmunoGen, Inc. (IMGN): Debt Offering News

IMGN – Files mixed securities shelf offering.

Key Facts Surrounding This News Item

  • IMGN had a POWR Rating of A (Strong Buy) coming into today.
  • IMGN was 1.25% above its 10-Day Moving Average coming into today.
  • IMGN was 7.26% above its 20-Day Moving Average coming into today.
  • IMGN was 27.95% above its 50-Day Moving Average coming into today.
  • IMGN was 52.90% above its 100-Day Moving Average coming into today.
  • IMGN was 65.50% above its 200-Day Moving Average coming into today.
  • IMGN had returned +76.76% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About ImmunoGen, Inc. (IMGN)

Immunogen develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts. View our full IMGN ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

IMGN at a Glance

IMGN Current POWR Rating™
Overall POWR Rating™
IMGN Current Price $9.03 2.27%
More IMGN Ratings, Data, and News

IMGN Price Reaction

The day of this event (Mar. 7, 2018)
IMGN Closing Price$11.65 2.82%
IMGN Volume2,283,300
25.22% from avg
Leading up to this event
IMGN 1-mo return25.75%
After this event
IMGN 1-day return5.00%
IMGN 3-day return2.33%
IMGN 5-day return2.16%

IMGN Price Chart

More ImmunoGen, Inc. (IMGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All IMGN News
Page generated in 1.128 seconds.